Adagrasib versus docetaxel in KRAS G12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

Journal:
The Lancet
Published:
Affiliations:
23
Authors:
193
Institutions Authors Share
Mirati Therapeutics, Inc., United States of America (USA)
4.045455
0.18
Rocky Mountain Cancer Centers, The US Oncology Network, United States of America (USA)
1.045455
0.05
Hospital Universitari Son Espases, Spain
1.045455
0.05
Airway Research Center North (ARCN), Germany
1.045455
0.05
State Key Laboratory of Translational Oncology, CUHK, China
1.045455
0.05
Antwerp University Hospital (UZA), UA, Belgium
1.045455
0.05
La Fe University Hospital, Spain
1.045455
0.05
Institute of Cancer Research (ICO), France
1.045455
0.05
Chonnam National University Hwasun Hospital (CNUHH), South Korea
1.045455
0.05
Candiolo Cancer Institute (FPO-IRCCS), Italy
1.045455
0.05
Metropolitan Hospital, Greece
1.045455
0.05
Shanghai Chest Hospital, SJTU, China
1.045455
0.05
IRCCS National Cancer Institute (INT) Milan, Italy
1.045455
0.05
IRCCS European Institute of Oncology (IEO), Italy
1.045455
0.05
Sichuan Cancer Hospital, China
1.045455
0.05
Vall d'Hebron University Hospital (HUVH), ICS, Spain
0.545455
0.02
Autonomous University of Barcelona (UAB), Spain
0.545455
0.02
Institute Gustave-Roussy (IGR), France
0.545455
0.02
University of Paris-Saclay, France
0.545455
0.02
Hôpital Louis Pradel, France
0.378788
0.02
Claude Bernard University Lyon 1 (UCBL), France
0.378788
0.02
Cancer Research Center of Lyon (CRCL), France
0.378788
0.02